Pharming Group (NASDAQ:PHAR - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $7.74, but opened at $8.69. Pharming Group shares last traded at $8.67, with a volume of 8,487 shares changing hands.
Analyst Ratings Changes
A number of research analysts have commented on PHAR shares. Jefferies Financial Group started coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a "buy" rating and a $14.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, December 17th.
Get Our Latest Report on PHAR
Pharming Group Stock Performance
The business's 50-day moving average price is $9.05 and its 200-day moving average price is $8.57. The stock has a market cap of $623.16 million, a PE ratio of -35.23 and a beta of -0.10. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, equities research analysts expect that Pharming Group will post -0.2 earnings per share for the current fiscal year.
Institutional Trading of Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is owned by institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
